25 reports

Istaroxime (CVie Therapeutics) PB-## (PhaseBio Pharmaceuticals) omecamtiv mecarbil (Cytokinetics & Amgen) CXL-## (Bristol Myers Squibb) Research Findings Kidney Dysfunction - Predictor of Acute Heart failure Genetic Influence on Heart Disease among African Americans Higher Body Mass

  • Heart Failure
  • Therapy
  • Europe
  • United States
  • World
  • Aetiologies of Heart Failure

Clinical status DISEASE PROGNOSIS & CLINICAL COURSE VARIATION BY GEOGRAPHY/ ETHNICITY ITEM Myocardial remodelling and severity of heart dysfunction Biomarkers of neurohormonal activation Other biomarkers Genetic testing Cardiovascular co-morbidities Non-cardiovascular co-morbidities

  • Cardiovascular Disease
  • Chronic Disease
  • Heart Failure
  • Pathology
  • Europe

CER-## WAS FURTHER EVALUATED IN TWO PHASE IIA TRIALS FOR RARE GENETIC CONDITIONS ASSOCIATED WITH ATHEROSCLEROSIS.

  • Heart Failure
  • World
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.

Increasing prevalence of diabetes, genetic factors, lifestyle factors such as junk food, tobacco consumption, substance abuse, alcohol addiction are expected to significantly contribute to the end-stage cardiovascular disease population and thereby increase the demand for chronic MCS therap

  • Heart Failure
  • HeartWare International, Inc.
  • Jude Medical, Inc.
  • ReliantHeart
  • Thoratec Corporation

As a result, certain genetic polymorphisms, drugs, and diet can interfere with this process (Holmberg et al., 2014).

  • Heart Failure
  • Europe
  • AstraZeneca PLC
  • NSTEMI group
  • The Medicines Company

genetic diseases December 2013: Together with Regeneron Pharmaceuticals Inc., the company announces an innovative collaboration with the ACC focused on improving clinical research on alirocumab December 2013: The EMA approves Merial' s Broadline for broad spectrum parasite treatment and

  • Heart Failure
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Cardiac Management
  • Clinical Trial
  • Heart Failure
  • United States
  • GlobalData's company
  • Clinical Trial profile. 55 Trial Title
  • Clinical Trial profile. 589 Trial Title

Genetically Defined Population with a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial Effect of Dalcetrapib Versus Placebo on CV Risk in a Genetically Defined Population with a Recent ACS (dal-GenE) GDCT## NCT##, DAL-##; GDC##; GDCT##; 2015-##-##; Eu

  • Acute Coronary Syndrome
  • Cardiovascular Disease
  • Clinical Trial
  • Heart Failure
  • AstraZeneca PLC

" MHI' S RECENT NEW GENETIC DISCOVERY SIGNIFICANTLY IMPROVES THE PROBABILITY OF A SUCCESSFUL PHASE III STUDY.

  • Cardiology
  • Heart Failure
  • United States
  • Product Initiative
  • Bayer AG
  • Clinical Trial profile. 33 Trial Title
  • Clinical Trial profile. 581 Trial Title

DalCor secured a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and all other CETP inhibitors.

  • Acute Coronary Syndrome
  • Cardiovascular Disease
  • Clinical Trial
  • Heart Failure
  • AstraZeneca PLC

It offers its products in the therapeutic areas of oncology, metabolic diseases; neurology, genetic disorders, women' s health and respiratory.

  • Heart Failure
  • Pharmaceutical
  • Therapy
  • United States
  • GlobalData's company
  • FEATURED NEWS & PRESS RELEASES

The drug candidate is a genetic fusion product, where VPAC##-selective vasoactive intestinal peptide (VIP) has been genetically engineered using the elastinlike biopolymer (ELP).

  • Heart Failure
  • Therapy
  • United States
  • World
  • Product Initiative

Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects with Coronary Heart Disease Effect of CYP##A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin (ECGPPA) GDCT## NCT##, YWLCSY-##; ##; GZJQZYY-##; ATR-##; GD##; ##

  • Cardiology
  • Clinical Trial
  • Heart Failure
  • World
  • Product Initiative

" MHI' s recent new genetic discovery significantly improves the probability of a successful Phase III study.

  • Acute Coronary Syndrome
  • Cardiology
  • Cardiovascular Disease
  • Heart Failure
  • Bayer AG
  • Cardiovascular Disease
  • Heart Failure
  • Neurological Disorder
  • Product Initiative
  • GlobalData's company
  • Clinical Trial profile. 889 Trial Title
  • 5. All the trials included are unique trials.

Genetic Individual Variations Drug-supplement Interactions on Intestinal Absorption and Its Genetic Individual Variations GDCT## UMIN##, R## Cardiovascular Atherosclerosis, Cardiovascular Risk Factors, Congestive Heart Failure (Heart Failure), Coronary Artery Dis

  • Cardiovascular Disease
  • Chronic Disease
  • Clinical Trial
  • Heart Failure
  • World
  • STEM CELL THERAPY FOR HEART FAILURE
  • R&D Progress

THE DRUG CANDIDATE IS A GENETIC FUSION PRODUCT, WHERE VPAC##-SELECTIVE VASOACTIVE INTESTINAL PEPTIDE (VIP) HAS BEEN GENETICALLY ENGINEERED USING THE ELASTIN-LIKE BIOPOLYMER (ELP).

  • Cardiovascular Disease
  • Gene Therapy
  • Heart Failure
  • United States
  • Product Initiative
  • CONGESTIVE HEART FAILURE (HEART FAILURE) - PIPELINE BY ANGES MG INC, H2 2017
  • 8-MI - DRUG PROFILE

THE DRUG CANDIDATE IS A GENETIC FUSION PRODUCT, WHERE VPAC##-SELECTIVE VASOACTIVE INTESTINAL PEPTIDE (VIP) HAS BEEN GENETICALLY ENGINEERED USING THE ELASTIN-LIKE BIOPOLYMER (ELP).

  • Cardiovascular Disease
  • Chronic Disease
  • Heart Failure
  • United States
  • Product Initiative
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY AMARANTUS BIOSCIENCE HOLDINGS INC, H2 2017
  • CORONARY ARTERY DISEASE (CAD) (ISCHEMIC HEART DISEASE) - PIPELINE BY ANGES MG INC, H2 2017

The company specializes in research and development (R& D) and practical application of genetic medicine.

  • Cardiovascular Disease
  • Coronary Artery Disease
  • Heart Failure
  • United States
  • Product Initiative

The studies evaluated genetic " markers" to determine which gene abnormalities may be associated with dangerous heart rhythms that can lead to sudden cardiac death (SCD).

  • Cardiac Management
  • Cardiology
  • Clinical Trial
  • Heart Failure
  • GlobalData's company

REPORT COVERS PRODUCTS FROM THERAPY AREAS ONCOLOGY, INFECTIOUS DISEASE, CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, GASTROINTESTINAL, GENETIC DISORDERS, IMMUNOLOGY AND OTHER DISEASES WHICH INCLUDE INDICATIONS HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS (AIDS), ACUTE MYELOCYTIC LEUKEMIA (AML,

  • Heart Failure
  • Hospital
  • Targeted Therapy
  • Therapy
  • Juventas Therapeutics, Inc.

Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects with Coronary Heart Disease Effect of CYP##A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin (ECGPPA) GDCT## NCT##, YWLCSY-##; ##; GZJQZYY-##; ATR-##; GD##; ##

  • Cardiovascular Disease
  • Coronary Artery Disease
  • Heart Failure
  • World
  • Product Initiative
  • Clinical Trial profile. 1196 Trial Title

Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure GDCT## NCT##, CELL-## Cardiovascular Cardiomyopathy, Congestive Heart Failure (Heart Failure), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy (DNA, N-Terminal Prohormone Of Brain Natriuretic Peptide

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Heart Failure
  • World

These products include Algisyl-LVR, cardiac stem-cell modulators, and cellular and genetic therapies delivered as stand-alone treatments, or in combination with the company' s proprietary biopolymer matrix system.

  • Clinical Trial
  • Heart Failure
  • Prosthesis
  • United States
  • GlobalData's company

The drug candidate is a genetic fusion product, where VPAC##-selective vasoactive intestinal peptide (VIP) has been genetically engineered using the elastin-like biopolymer (ELP).

  • Cardiovascular Disease
  • Chronic Disease
  • Heart Failure
  • United States
  • Product Initiative